Inflammatory Bowel Disease

Discussing the latest advances in Crohn’s disease and ulcerative colitis

Share this:
December 24th, 2014

Therapeutic Drug Monitoring of Anti-TNF Therapy

By Margaret Shepard, Communications Associate

Therapeutic drug monitoring is now extending to newer biologics, including TNF inhibitors such as infliximab, a chimeric monoclonal antibody, and adalimumab, a fully human monoclonal antibody. Although these drugs have improved outcomes for some refractory patients, they have been unsatisfactory for others.

Edward V. Loftus Jr., M.D., comments on the effectiveness of therapeutic drug monitoring in a recent Digestive Diseases Update.

For more information about IBD, visit mayoclinic.org/ibd.

Dr. Loftus is a gastroenterologist at Mayo Clinic.

Tags: Anti-TNF agents, drug therapy, Edward Loftus, IBD, News Alerts, therapeutic drug monitoring

Comment

Please login or register to post a comment.
Contact Us · Privacy Policy